CD133 antigen expression in ovarian cancer

被引:74
作者
Ferrandina, Gabriella [1 ,2 ]
Martinelli, Enrica [1 ]
Petrillo, Marco [2 ]
Prisco, Maria Grazia [1 ]
Zannoni, Gianfranco [3 ]
Sioletic, Stefano [3 ]
Scambia, Giovanni [2 ]
机构
[1] Catholic Univ, Dept Oncol, Gynecol Oncol Unit, Campobasso, Italy
[2] Univ Cattolica Sacro Cuore, Gynecol Oncol Unit, I-00168 Rome, Italy
[3] Univ Cattolica Sacro Cuore, Inst Human Pathol, I-00168 Rome, Italy
关键词
TUMOR-INITIATING CELLS; STEM-CELLS; MARKER CD133; PROSPECTIVE IDENTIFICATION; MALIGNANT-MELANOMA; MESSENGER-RNA; CHEMORESISTANCE; GLIOBLASTOMA;
D O I
10.1186/1471-2407-9-221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Much attention has been recently focused on the role of cancer stem cells (CSCs) in the initiation and progression of solid malignancies. Since CSCs are able to proliferate and self-renew extensively, thus sustaining tumor growth, the identification of CSCs through their antigenic profile might have relevant clinical implications. In this context, CD133 antigen has proved to be a marker of tumor cells with stemness features in several human malignancies. The aim of the study was to investigate the clinical role of the immunohistochemically assessed expression of CD133 in a large single Institution series of ovarian cancer patients. Methods: The study included 160 cases admitted to the Gynecologic Oncology Unit, Catholic University of Campobasso and Rome. CD133 antigen was identified by the monoclonal mouse anti-CD133-1 antibody (clone CD133 Miltenyi biotec). Results: In the overall series CD133 positive tumor cells were observed in 50/160 (31.2%) cases. A diffuse cytoplasmic pattern was identified in 30/50 (60.0%), while an apical cytoplasmic pattern was found in 20/50 (40.0%) of CD133 positive tumors. As of September 2008, the median follow up was 37 months (range: 2-112). During the follow up period, progression and death of disease were observed in 123 (76.9%), and 88 (55.0%) cases, respectively. There was no difference in TTP between cases with negative (median TTP = 23 months) versus positive CD133 expression (median TTP = 24 months) (p value = 0.3). Similar results were obtained for OS. When considering the TTP and OS curves according to the pattern of CD133 expression, a trend to a worse prognosis for cases with diffuse cytoplasmic versus the apical cytoplasmic pattern was documented, although the statistical significance was not reached. Conclusion: The immunohistochemical assessment of CD133 expression seems not to provide additional prognostic information in ovarian cancer patients. The role of the different pattern of CD133 immunoreaction deserves further investigation in a larger series.
引用
收藏
页数:9
相关论文
共 38 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   Epigenetic regulation of CD133 and tumorigenicity of CD133+ovarian cancer cells [J].
Baba, T. ;
Convery, P. A. ;
Matsumura, N. ;
Whitaker, R. S. ;
Kondoh, E. ;
Perry, T. ;
Huang, Z. ;
Bentley, R. C. ;
Mori, S. ;
Fujii, S. ;
Marks, J. R. ;
Berchuck, A. ;
Murphy, S. K. .
ONCOGENE, 2009, 28 (02) :209-218
[3]   Glioma stem cells promote radioresistance by preferential activation of the DNA damage response [J].
Bao, Shideng ;
Wu, Qiulian ;
McLendon, Roger E. ;
Hao, Yueling ;
Shi, Qing ;
Hjelmeland, Anita B. ;
Dewhirst, Mark W. ;
Bigner, Darell D. ;
Rich, Jeremy N. .
NATURE, 2006, 444 (7120) :756-760
[4]   Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer [J].
Bapat, SA ;
Mali, AM ;
Koppikar, CB ;
Kurrey, NK .
CANCER RESEARCH, 2005, 65 (08) :3025-3029
[5]   Exploring the role of cancer stem cells in radioresistance [J].
Baumann, Michael ;
Krause, Mechthild ;
Hill, Richard .
NATURE REVIEWS CANCER, 2008, 8 (07) :545-554
[6]   CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles [J].
Beier, Dagmar ;
Hau, Peter ;
Proescholdt, Martin ;
Lohmeier, Annette ;
Wischhusen, Joerg ;
Oefner, Peter J. ;
Aigner, Ludwig ;
Brawanski, Alexander ;
Bogdahn, Ulrich ;
Beier, Christoph P. .
CANCER RESEARCH, 2007, 67 (09) :4010-4015
[7]  
BLINGMAIER S, 2008, J MOL MED, V86, P1025
[8]   Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].
Bonnet, D ;
Dick, JE .
NATURE MEDICINE, 1997, 3 (07) :730-737
[9]   Prospective identification of tumorigenic prostate cancer stem cells [J].
Collins, AT ;
Berry, PA ;
Hyde, C ;
Stower, MJ ;
Maitland, NJ .
CANCER RESEARCH, 2005, 65 (23) :10946-10951
[10]  
COX DR, 1972, J R STAT SOC B, V34, P187